Charles River Laboratories International (NYSE:CRL) Shares Cross Above 200 Day Moving Average – Should You Sell?

Charles River Laboratories International, Inc. (NYSE:CRL) shares crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $226.13 and traded as high as $310.53. Charles River Laboratories International shares last traded at $302.7710, with a volume of 941,309 shares traded.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent analyst reports. Morgan Stanley boosted their target price on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a report on Monday. Royal Bank Of Canada upped their price objective on Charles River Laboratories International from $282.00 to $322.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research note on Wednesday, July 1st. TD Cowen lifted their price target on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the stock a “buy” rating in a report on Friday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $302.33.

Charles River Laboratories International Stock Down 1.9%

The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The company has a market cap of $14.34 billion, a P/E ratio of -61.93, a price-to-earnings-growth ratio of 2.82 and a beta of 1.40. The stock has a fifty day moving average price of $288.83 and a two-hundred day moving average price of $227.16.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon Parisotto sold 981 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $308.44, for a total transaction of $302,579.64. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,482,671.08. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the transaction, the chief executive officer owned 36,013 shares of the company’s stock, valued at $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 91,971 shares of company stock valued at $26,033,968. Company insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently modified their holdings of the company. Activest Wealth Management grew its holdings in Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock valued at $82,000 after purchasing an additional 57 shares during the period. Empirical Finance LLC lifted its holdings in shares of Charles River Laboratories International by 4.4% during the 2nd quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock valued at $333,000 after purchasing an additional 62 shares in the last quarter. Glenmede Trust Co. NA grew its position in shares of Charles River Laboratories International by 2.8% in the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 73 shares during the period. Syon Capital LLC increased its stake in Charles River Laboratories International by 2.4% during the 2nd quarter. Syon Capital LLC now owns 3,547 shares of the medical research company’s stock worth $804,000 after purchasing an additional 83 shares in the last quarter. Finally, Brown Miller Wealth Management LLC raised its holdings in Charles River Laboratories International by 7.0% during the 1st quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock worth $220,000 after buying an additional 84 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.